Studies have shown that combining imatinib with the allosteric AKT inhibitor MK‐2206 (Type II) results in significant synergy in both imatinib‐sensitive and resistant GIST cells, as well as in xenograft animal models [80]. Here, AKT1 is linked to gastrointestinal stromal tumor.